Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Indications And Results After Chest Wall Resection For Recurrent Mesothelioma.

B. Burt, S. O. Ali, M. Dasilva, B. Yeap, W. Richards, E. Baldini, D. Sugarbaker
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE The ipsilateral hemithorax is the most common site of recurrence after surgical resection for malignant pleural mesothelioma. Salvage treatment has generally been ineffective. We reviewed the outcomes after resection of isolated ipsilateral chest recurrence after cytoreductive surgery in patients with malignant pleural mesothelioma. METHODS Patients with malignant pleural mesothelioma who underwent initial surgical resection at our institution from 1988 to 2011 and were subsequently treated for localized recurrence with an additional chest resection were identified and their data retrospectively reviewed. RESULTS A total of 1142 patients underwent either extrapleural pneumonectomy (n = 794) or pleurectomy/decortication (n = 348). Of the patients who returned for follow-up, 47 (4.1%) had chest wall recurrence amenable to resection. The location of recurrence was predominantly incisional (49%) and/or costophrenic (38%). The median time to recurrence after either extrapleural pneumonectomy or pleurectomy/decortication was 16.1 months (range, 2.7-58.2). No 30-day mortality was found for chest wall resection, and the median length of stay in the hospital was 3 days (range, 0-12). The median overall survival duration after chest wall resection correlated positively with the time to recurrence (epithelial: median, 8.9, 17.2, and 35.8 months for a time to recurrence of <12, 12 to <24, and ≥24 months, respectively; biphasic: median, 2.7 and 15.9 months for a time to recurrence of <10 and ≥10 months, respectively). CONCLUSIONS Chest wall resection is a safe and effective therapeutic option in the management of localized chest wall recurrence of malignant pleural mesothelioma. The time to recurrence appears to be predictive of the expected survival benefit in both epithelial and biphasic malignant pleural mesothelioma.
This paper references
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1634/theoncologist.2010-0185
What is the role of radiotherapy in malignant pleural mesothelioma?
A. Price (2011)
10.1097/JTO.0b013e3181a5292c
Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy
V. Gupta (2009)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1016/J.LUNGCAN.2004.04.006
Pathology of malignant mesothelioma.
E. Marck (2004)
10.1016/j.athoracsur.2011.05.052
Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival.
B. Burt (2011)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/j.lungcan.2007.12.022
Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.
M. Metintas (2008)
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesotheli
N O’Rourke (2007)
10.1016/S0022-5223(97)70397-0
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.
U. Pastorino (1997)
10.1007/s11864-011-0146-4
The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma
M. Zauderer (2011)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.5555/URI:PII:0093775481900403
Clinical presentation and natural history of benign and malignant mesothelioma.
K. Antman (1981)
10.1016/j.athoracsur.2009.09.028
Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.
L. Politi (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar